Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 215

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 215
---
.34% – 4.53 | % |
| Expected volatility         |     |             | 111.8% – 113.2 | % |
| Dividend yield              |     |             |              0 | % |
| Contractual life (in years) |     |             |             10 |   |

<div align='center'>F-26</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

Successor:

| 1. | Amendment to the Company’s Global Share Incentive Plan (2021),                                                                         
 increasing the number of shares available for issuance under Company’s Global Share Incentive Plan (2021) to 20,000,000 (the           
 “Plan Amendment”). The Plan Amendment became effective on the date of the approval by the Board of Directors, but it                   
 is subject to approval by the holders of a majority of the voting power of the Company within 12 months, pursuant to section 422(b)(1) 
 of the Internal Revenue Code.                                                                                                          |

| 2. | A grant to the Successor’s former Chief Executive Officer 3,800,000                                                                   
 stock options at an exercise price of $0.001 per share. 1,900,000 options were fully vested upon grant and the remaining 1,900,000    
 options are scheduled to vest on a quarterly basis over two years in equal quarterly instalments of 237,500 options, beginning with   
 the quarter ended March 31, 2024. The options are exercisable within eight years from grant date. The aggregate grant date fair value 
 of such options was approximately $4,770.                                                                                             |

| 3. | A grant to the Chairman of the Board 160,000 stock options at an exercise                                                             
 price of $0.40 per share. 80,000 options were fully vested upon grant and the remaining 80,000 options are scheduled to vest on a     
 quarterly basis over 2 years in equal quarterly instalments of 10,000 options, beginning with the quarter ended March 31, 2024. The   
 options are exercisable within eight years from the grant date. The aggregate grant date fair value of such options was approximately 
 $190.                                                                                                                                 |

| b. | On November 11, 2024, following